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Abstract
Background: The effect of radiotherapy, in particular the application of different multi-fraction schedules in the
management of unstable spinal bone metastases (SBM), is incompletely understood. This study aims to compare
the radiological response regarding various dose and fractionation schedules of radiotherapy in the palliative
treatment of SBM.
Methods: We retrospectively assessed 1047 patients with osteolytic SBM, treated with palliative radiotherapy at our
department between 2000 and 2015. Lung cancer (40.2%), breast (16.7%) and renal cancer (15.2%) were the most
common solid tumors in this study. Different common multi-fraction regimen (5x4Gy, 10x3Gy, 14 × 2.5Gy and 20x2Gy)
were compared with regard to radiological response and recalcification at 3 and 6 months after radiotherapy. The
Taneichi score was used for classification of osteolytic SBM.
Results: Median follow up was 6.3 months. The median overall survival (OS) in the short-course radiotherapy (SCR)
group using less than 10 treatment fractions was 5.5 months vs. 9.5 months in the long-course radiotherapy (LCR)
group using in excess of 10 fractions (log rank p < .0001). Overall survival (OS) in the SCR group after 3 and 6 months
was 66.8 and 49.1%, respectively vs 80.9 and 61.5%, respectively in the LCR group.
17.6% (n = 54/306) and 31.1% (n = 89/286) of unstable SBM were classified as stable in the SCR group at 3 and 6 months
post radiotherapy, respectively (p < .001 for both). In the LCR group, 24.1% (n = 28/116) and 34.2% (n = 38/111) of
unstable SBM were stabilized after 3 and 6 months, respectively (p < .001 for both).
Conclusions: Our study shows no significant difference in stabilization achieving recalcification rates between multi-
fraction schedules (SCR vs. LCR) in the palliative management of unstable SBM. Both groups with multi-fraction regimen
demonstrate a stabilizing effect following 3 and 6 months after radiotherapy.
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Background
Spinal bone metastases occur in up to 40% of tumor
patients during the course of the disease [1].
Associated spine pain, immobility, pathological fractures
and neurological deficits substantially reduce the quality
of life. Unstable SBMs in particular require coordinated
multimodal therapy. In the palliative multidisciplinary
approach, surgical intervention of the cervical and thora-
columbar spinal instability can achieve rapidly improved
functional results [2–4]. Less-invasive surgery followed by
early adjuvant radiotherapy could be a promising, safe and
effective treatment option for achieving solid and durable
stability in selected patients without metastatic spinal cord
compression (MSCC) [3].
If surgical intervention is not possible, external beam
radiotherapy (EBRT) is an established treatment for
stabilization in the palliative management of patients with
unstable SBM [5–11]. Numerous studies have investigated
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the influence of total dose and fractionation regarding to
the pain response [12–23].
However, the optimal total dosage and fractionation in
relation to the re-ossification of the unstable SBMs is still
unclear. Chow and colleges did not find a significant differ-
ence in bone density between 8 Gy in a single fraction and
20 Gy in 5 fractions or 30 Gy in 10 fractions in patients
with breast cancer 3 months follow up after irradiation [5].
Reinhold et al. described an increase in bone density over
60% of lytic vertebral metastases at 3 months after 40 Gy
in 20 fractions in subgroup with 13 participants [6].
We initiated this retrospective mono-centric analysis to
investigate the influence of different fractionation schemes
and doses on the re-ossification rate in metastatic solid
cancers. To the best of our knowledge, no comparable
study has been described in the literature so far.
Methods
Assessment of the radiological response
From 2000 to 2015, 1047 patients with histologically
confirmed solid tumors and osteolytic SBM were treated
with external beam RT (EBRT) at our department. Patient
data were taken from the cancer registry of the National
Center for Tumor Diseases (Heidelberg, Germany). SBM
were diagnosed using computed tomography (CT) and
magnetic resonance imaging (MRI).
The stability of osteolytic SBM was examined according
to the Taneichi score [24] based on the CT imaging before
EBRT and at 3 and 6 months after treatment. This score
classified osteolytic SBM as “stable” or “unstable” by defin-
ition of risk factors such as tumor size and the degree of
costovertebral joint destruction for the thoracic region (Th
1 to 10) and tumor size and the degree of pedicle destruc-
tion for the lumbar segments (Th 11 to L5). Osteolytic
metastases were rated on a scale from A to G, whereby
subtypes A to C were defined as stable, and subtypes D to
G as unstable. In cases with multiple metastases in which
only one lesion was detected as unstable, the Taneichi
score was defined as unstable.
After 3 and 6 months, 621 and 590 cases were evaluated
in the SCR group vs. 205 and 197 cases in the LCR group,
respectively. The initial classification of the osseous me-
tastases into stable or unstable was made by experienced
radiologists based on CT imaging. Subsequent evaluation
was performed after 3 and 6 months using the baseline
imaging, the changes in bone density, and the extent of
the stabilizing resclerosing of the osteolytic lesions.
Bone density in irradiated vertebral bodies was
assessed at baseline and at 3 and 6 months after RT.
Bone density was assessed with the Syngo Osteo CT
workstation in manually selected regions of interest
(ROIs). Hounsfield units (HU) were used for bone dens-
ity measurements. Siemens Somatom Sensation Open
(Siemens, Erlangen, Germany) was used for all CT
examinations. Measurements were carried out at the
appropriate site by a single physician.
This study was approved by the independent ethics
committee of the Heidelberg Ethics Committee on 22
October 2012 (# S-513/2012). Due the retrospective
design, informed consent was not required. This retro-
spective study analyzes/utilizes the cumulative patient
data taken from previously published studies, which also
evaluated the influence of multi-fraction radiotherapy on
the stability of osteolytic SBM, but employed entirely
different aspects [7, 10, 25, 26].
Statistical analysis
The empirical distribution of continuous variables is
described by the number of observations, mean and stand-
ard deviation; scores were described by median and range,
the description of categorical variables includes the num-
ber and percentage of patients belonging to the relevant
categories. Possible differences between the group of
patients with <= 10 fractions compared to those with > 10
fractions were evaluated with t-test for continuous data,
with Mann-Whitney U-test for ordinal data (scores) and
with chi-square-test for categorical data. Multivariate ana-
lysis was performed using binary logistic regression. This
analysis evaluates possible prognostic factors of baseline
stability, namely age, gender, KPS, primary site, localization
and number and type of metastasis, calculated separately
for patients with SCR or LCR.
“Bone survival” (BS) was defined as the time from initial
diagnosis of SBM until death. The time of site irradiation
was not equal to the time of initial diagnosis of SBM.
Overall survival (OS) was defined as time from the begin-
ning of RT until death. We estimated patient survival
using the Kaplan–Meier method. Patients were censored
on the basis of whether or not they were alive. Possible
differences were reported with p-values of the log-rank
tests. All statistical analyses were done using the SAS soft-
ware version 9.4 (SAS Institute, Cary, NC, USA).
Patient’s characteristics
Palliative EBRT was required for analgesia in 53.9%
(n = 564), stabilizing intention in 42.6% (n = 446) and
for neurological deficits in 2.2% (n = 23). Only 14
patients (1,3%) had adjuvant irradiation after prior
surgical intervention.
Thus, 534 cases (51%) were classified as unstable
SBM, and a stabilizing orthopedic corset was indicated
in 475 cases (45.4%). Because the Taneichi score applica-
tion is limited to thoracic and lumbar spine segments, in
this study the most SBM were consequently localized in
60.7% (n = 635), in the thoracic spine and in lumbar
spine 39.2% (n = 410).
Patients’ mean age at diagnosis of SBM was 63.1 years
(SD +/− 11.1 years), and median Karnofsky performance
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status (KPS) was 80.0% (range 30–100) [27]. Gender was
well balanced with 578 male (55.2%) and 469 female
patients (44.8%).The most frequent tumor type was
non-small cell lung cancer (NSCLC) with 40.6% (n = 425),
followed by breast cancer 16.7% (n = 175) and renal cancer
15.2% (n = 159). Antiresoptive treatment such as bisphos-
phonate or denosumab was received by 62.6% partici-
pants. The characteristics of all participants included in
this analysis are summarized in Table 1.
Radiotherapy
After virtual simulation, RT was performed as irradiation of
the involved vertebral body as well as the vertebrae imme-
diately above and below using 6 MV individually-formed
beams after CT-scan based 3D-planning. Palliative radio-
therapy was delivered in most cases with 10 × 3 Gy (72.3%;
n = 757), 20 × 2 Gy (17.6%; n = 184), 14 × 2.5 Gy (8.8%; n =
92) and other individual doses (1.4%; n = 15). The therapy
schedule was prescribed according to general performance
status, histology of primary solid tumor, prognosis and life
expectancy.
Two multi-fraction groups was formed: patients who
received shot course radiotherapy (SCR) with </=10
fractions vs. patients undergoing long course radiother-
apy (LCR) > 10 fraction.
Results
Median follow-up time for both groups was 6.3 months
(range 0.03–283 months).
Initially, 51% (n = 534) of 1047 SBM were classified as
unstable SBM, of which 377 were in the SCR and 157 in
the LCR group.
After 3 months, 621 with SCR and 205 patients with
LCR could be re-examined, the originally unstable SBM
were reclassified as stable in 17.6% (54/306) of the cases
for the SCR group vs. 24.1% (28/116) for the LCR group
(McNemar’s test p < .001). After 6 months, 590 with SCR
and 197 patients with LCR could be re-examined, and
31.1% of initially unstable SBM (89/286) were classified as
stable in the SCR group vs 34.2% (38/111) for the LCS
group. The frequent reasons for lost of follow up were
worsening of the condition, continuation of therapy in
other clinics or death.
Conversely, in the SCR group at 3 and 6 months follow
RT 1.6% (5/315) and 2.0% (6/304) of the stable SBM were
reclassified as unstable. A numerically comparable desta-
bilizing rate was also found in the LCR group after 3 and
6 months respectively 4.5% (4/89) and 7% (6/86) (Table 2).
The median overall survival (OS) in the SCR group was
5.5 months vs. 9.5 months in the LCR (log rank
p < .0001). The OS in the SCR group after 3 and 6 months
was 66.8 and 49.1%, respectively vs 80.9 and 61.5%,
respectively in the LCR group (Fig. 1). The stability
dependent OS analysis showed no significant difference
either for both groups or separately (log rank test for both
groups: p = 0.631, SCR: p = 0.181 and LCR p = 0.946). At
the last follow-up, 3.8% (n = 26) patients were still alive in
the SCR group vs. 6.1% (n = 17) in the LCR group (chi
square test p = 0.049).
The median bone survival (BS) in SCR group was
6.7 months vs. 12.2 months in the LCR group (log rank
p < .0001). (Fig. 2).
Gender had no influence on stabilization rate in both
groups. SCR was delivered in 769 cases (73.4%) vs. LCR in
278 cases (26.6%). Antiresoptive treatment was prescribed
to 62.6% of all patients, 66.7% in the SCR collective vs.
51.1% in the LCR group (chi square test p < 0.001).
The univariate analysis within the SCR group showed
a significant difference in KPS between stable and
unstable SBM (Mann-Whitney U-test, p = 0.027). Multi-
variate analysis in the SCR group showed a significant
association between multiple metastases and instability
(logistic regression, p < 0.0001) (Table 3).
The univariate analysis within the LCR group found a
significant relationship between age and unstable SBM
(Mann-Whitney U-test, p = 0.034). Multivariate analysis
in this group showed a significant association between
pulmonary metastases and instability (logistic regression,
p < 0.013) (Table 3).
Discussion
This retrospective study compared radiological response
by various dose and fractionation schedules of radiother-
apy in the palliative treatment of SBM. All multi-fraction
schedules showed a stabilizing effect, and there was
stabilization observed both in the SCR and LCR groups.
We determined a statistically significant stabilizing effect
after 3 and 6 months within each group (p < .0001).
There was no difference between the groups.
There are few relevant studies that investigate the
impact of fractionation on remineralization, but not
stabilization of lytic bone lesions. The available data
show a great heterogeneity of the primary endpoints and
patient collective. Therefore, our results are difficult to
compare with other studies.
The reossification of osteolysis as a surrogate for
radiotherapeutic response has been widely investigated
and integrated into daily routine. However, the relevant
studies show very contradictory results. A prospective
study by Chow et al. was conducted to examine the
feasibility of the evaluation based on CT exams, the
remineralization of the osteolytic bone lesions at
3 months after palliative radiotherapy. Radiotherapy was
applied with 8 Gy in a single fraction vs. 20 Gy in 5 frac-
tions or 30 Gy in 10 fractions. Of 25 breast cancer par-
ticipants, 11 patients suffered from osteolytic vertebral
bone metastasis. Bisphosphonate therapy was allowed.
At the 3 months follow up no significant change of the
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median % bone density was assessed. There was no fur-
ther description of the lytic metastases with regard to
stability prior and after irradiation [5].
In contrast, Koswig and Budach showed a significant
difference in recalcification of the osteolytic bone metas-
tasis in favor of the fractionated group in a randomized
Table 1 Demographics
<= 10 fractions > 10 fractions All patients p-value
n = 769 n = 278 n = 1047
n % n % n %
Age (years)
Mean (SD) 63.3 +/− 10.7 62.5 +/− 12.0 63.1 +/− 11.1 0.330a
Gender
Male 435 56.6 143 51.4 578 55.2 0.141b
Female 334 43.4 136 48.6 469 44.8
Karnofsky-index
Median (range) 80 (40–100) 80 (30–100) 80 (30–100) 0.696c
Primary site < 0.001b
NSCLC 356 46.3 69 24.8 425 40.6
Breast cancer 106 13.8 69 24.8 175 16.7
Renal cancer 88 11.4 71 25.5 159 15.2
Other 219 28.5 69 24.8 288 27.5
Localization of metastases 0.476b
Cervical 1 0.1 1 0.3 2 0.2
Thoracic 460 59.8 145 63.0 635 60.7
Lumbar 308 40.1 102 36.7 410 39.1
Number of metastases 0.329b
Mean (SD) 2.6 +/− 2.1 2.9 +/− 2.8 2.7 +/− 2.3 0.069a
Solitary 350 45.5 136 48.9 486 46.4
Multiple 419 54.5 142 51.1 561 53.6
Other distant metastases
Liver 203 26.4 60 21.6 263 25.1 0.112b
Brain 112 14.6 30 10.8 142 13.6 0.119b
Lung 185 24.1 74 26.6 259 24.7 0.396b
Tissue 55 7.2 12 4.3 67 6.4 0.097b
Antiresoptive treatment 513 66.7 142 51.1 655 62.6 < 0.001b
Chemotherapy 445 57.9 145 52.4 590 56.4 0.112b
Stable metastases 392 51.0 121 43.5 513 49.0 0.033b
Unstable metastases 377 49.0 157 56.5 534 51.0
Orthopedic corset 353 45.9 122 43.9 475 45.4 0.562b
Radiotherapy schedule
1 × 8 Gy 1 0.1
5 × 4 Gy 11 1.0
10 × 3 Gy 757 72.3
11 × 3 Gy 1 0.1
12 × 3 Gy 1 0.1
14 × 2.5 Gy 92 8.8
20 × 2 Gy 184 17.6
Baseline characteristics of participants. Explanation: Others: colon cancer, neuroendocrine cancer, prostata cancer, ovarian cancer, urothelial cancer, uterine cancer,
vulva cancer. Abbreviation: NSCLC non-small-cell lung carcinoma; at-test; bchi-square-test, cu-test
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two-arm (1 × 8 Gy vs. 10 × 3 Gy) trial. In the
multi-fraction group, a significant effect was assessed
only in patients with breast cancer (p < 0.001). No infor-
mation on stability was provided [8].
In line with above mentioned previous study,
Wachenfeld et al. assessed in 14 patients with
vertebral bone lesions of breast cancer different radio-
logical response of the irradiated bone varies depend-
ing on the form of metastasis. Accordingly, osteolytic
metastases generally showed an increase in CT dens-
ity to approximately 150% of the initial value at
3 months after the multi-fraction irradiation. This ef-
fect was further enhanced by additional chemotherapy
[28]. Two decades later, we showed similar results in
a retrospective analysis of 115 patients with 135
spinal metastases from the breast cancer. In contrast,
no correlation between differences in the bone density
and simultaneous chemotherapy was observed [7].
Notably, different fractionation showed no difference in
the recalcification rates of multiple myeloma bone
lesions [29]. The randomized trial by Rudzianskiene et al.
was conducted to compare two schedules (1 × 8 Gy vs.
10 × 3 Gy) in palliative treatment of multiple myeloma
lesions. The recalcification was measured in both groups 4
and 12 weeks follow irradiation. Remineralization oc-
curred in 32/101 patients (33.7%), of which 17 (53.2%)
were complete and 15 (46.2%) partial. No differences in
reossification were observed between 1 × 8 Gy vs. 10 × 3
Gy schedules [29].
Table 2 Stability after 3 and 6 months in both groups
<= 10 fractions 3 months
Unstable Stable Total
n % n % n %
Unstable 252 82.4 54 17.6 306 49.3
Stable 5 1.6 310 98.4 315 50.7
621 100
> 10 fractions
Unstable 88 75.9 28 24.1 116 56.6
Stable 4 4.5 85 95.5 89 43.4
205 100
<= 10 fractions 6 months
Unstable Stable Total
n % n % n %
197 68.9 89 31.1 286 48.5
6 2.0 298 98.0 304 51.5
590 100
> 10 fractions
Unstable 73 65.8 38 34.2 111 56.4
Stable 6 7.0 80 93.0 86 43.7
197 100
Fig. 1 Overall survival of both arms, time in years
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The systematic review by Groenen estimated the
impact of EBRT in stabilizing metastatic bone lesions, in
particular the effect the radiotherapy alone and com-
bined with bisphosphonates or RANK ligands
(RANKL). The emphasis of this study was placed on
biomechanical characteristics such as bone quality
changes and pathological fractures. It was concluded
that no sufficient evidence exist, which demonstrate
the positive influence of the EBRT on bone density
and pathological fracture respective [30]. The inci-
dence of pathological fractures in all patients in our
study at baseline and 6 months was moderate by 7.4
and 9% respectively [31]. None of the relevant studies
provided information on the influence of fractionation
on the stability of osseous metastases.
Despite the lack of evidence, our results confirm
the clinical experience that radiotherapy is an effect-
ive local treatment for unstable SBM from solid tu-
mors. To the best of our knowledge, this was the
largest retrospective study to date investigating the in-
fluence of various multi-fraction palliative radiother-
apy regimen on the stability of SBM. A consequence
of this findings a prospective randomized study was
initiated in our department to investigate the influ-
ence of different palliative multi-fraction schemata on
the bone density of vertebral metastases [32].
In our cohort 62.6% of patients received antiresoptive
treatment. In comparison with our results, Udagawa and
co-worker reported higher rates of bone-target therapy
with 69% (n = 103) of 149 patients with untreated bron-
chial carcinoma and osseous metastases [33]. Another
study reported even higher rates with 89% in patients with
advanced breast cancer and osseous metastases [34]. In
group comparison, the prescription of antiresoptive treat-
ment in our trial was significant higher with 66.7% vs
51.1% in the SCR group (p < 0.001). These findings may
reflect a realization of palliative therapeutic approaches,
especially rapid pain relief by shorter life expectancy. This
difference in our study cannot be explained. Multicentric
international comparisons of prescription patterns of anti-
resoptive treatment would be necessary.
Statistically, the median OS and BS was significantly
better in the LCR group (9.5; 12.2 and 5.5; 6.7)
months respectively, (log rank p < .0001). Stability did
not impact OS in either group. Statistically, a signifi-
cant percentage of patients was alive in LRT group at
the time of the survey, which indirectly reflects the
common practice, particularly the influence of sub-
jective life expectancy estimation (KPS, extra osseous
disease extent) on the choice of multi-fraction regime
by radio-oncologists.
Although the strengths of our investigation include
the representative large collective and standardized
evaluation of bone density and stability of all osteolytic
lesions, several limitations must be acknowledged. In
addition to a retrospective character and the unequal
number of patients in the comparative groups (SRT >
LRT).
Fig. 2 Bone survival of both arms, time in years
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Table 3 Univariate and multivariate analysis in both groups
<= 10 fractions
stable instable p-value p-value (logistic Regression)
n = 377 n = 392
n % n %
Age (years)
Mean (SD) 62.6 +/− 10.4 64.0 +/− 11.0 0.084a 0.214
Gender
Male 219 55.9 216 57.3 0.690a 0.742
Female 173 44.1 161 42.7
Karnofsky- Index
Median (range) 80 (40,100) 70 (40,100) 0.027c 0.090
Primary site 0.933b 0.883
NSCLC 183 46.7 173 45.9
Breast cancer 55 14.0 51 13.5
Renal cancer 42 10.7 46 12.2
Other 112 28.6 107 28.4
Localization metastases 0.303b 0.637
Cervical/Thoracic 228 58.2 233 61.8
Lumbar 164 41.8 144 38.2
Number metastases < 0.0001b < 0.0001
Solitary 210 53.6 140 37.1
Multiple 182 46.4 237 62.9
Other distant metastases
Liver 102 26.0 101 26.8 0.809b 0.518
Brain 59 15.1 53 14.1 0.697b 0.759
Lung 95 24.2 90 23.9 0.907b 0.902
Tissue 35 8.9 20 5.3 0.051b 0.120
> 10 fractions
stable instable p-value p-value (log. Regression)
n = 121 n = 157
n % n %
Age (years)
Mean (SD) 60.7 +/− 12.7 63.8 +/− 11.3 0.034a 0.168
Gender
Male 60 49.6 83 52.9 0.588a 0.643
Female 61 50.4 74 47.1
Karnofsky- Index
Median (range) 80 (40,100) 70 (30,100) 0.063c 0.079
Primary site 0.575b 0.933
NSCLC 28 23.1 41 26.1
Breast cancer 28 23.1 41 26.1
Renal cancer 30 24.8 41 26.1
Other 35 28.9 34 21.7
Localization metastases 0.687b 0.970
Cervical/Thoracic 75 62.0 101 64.3
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Conclusion
Our study demonstrated no significant difference in
recalcification rates between various multi-fraction
schedules (SCR vs. LCR) in the palliative management of
unstable SBM. Use of shorter, equally potent schemata
may shorten hospitalization, increase the patients’ qual-
ity of life and save resources.
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